TW390887B - A method for chromatographic removal of prions - Google Patents
A method for chromatographic removal of prions Download PDFInfo
- Publication number
- TW390887B TW390887B TW086108949A TW86108949A TW390887B TW 390887 B TW390887 B TW 390887B TW 086108949 A TW086108949 A TW 086108949A TW 86108949 A TW86108949 A TW 86108949A TW 390887 B TW390887 B TW 390887B
- Authority
- TW
- Taiwan
- Prior art keywords
- patent application
- scope
- item
- gradient
- solution
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 102000029797 Prion Human genes 0.000 title abstract description 7
- 108091000054 Prion Proteins 0.000 title abstract description 7
- 238000005571 anion exchange chromatography Methods 0.000 claims abstract description 20
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims abstract description 6
- 238000010828 elution Methods 0.000 claims abstract 2
- 102000004169 proteins and genes Human genes 0.000 claims description 67
- 108090000623 proteins and genes Proteins 0.000 claims description 67
- 239000002245 particle Substances 0.000 claims description 43
- 230000001717 pathogenic effect Effects 0.000 claims description 43
- 150000003278 haem Chemical class 0.000 claims description 37
- 208000003251 Pruritus Diseases 0.000 claims description 25
- 241000283690 Bos taurus Species 0.000 claims description 24
- 238000000108 ultra-filtration Methods 0.000 claims description 19
- 230000002079 cooperative effect Effects 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 11
- 206010014599 encephalitis Diseases 0.000 claims description 10
- 102000001554 Hemoglobins Human genes 0.000 claims description 9
- 108010054147 Hemoglobins Proteins 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000005349 anion exchange Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 241001494479 Pecora Species 0.000 claims description 7
- 238000004587 chromatography analysis Methods 0.000 claims description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 125000002091 cationic group Chemical group 0.000 claims description 5
- 229920000642 polymer Chemical group 0.000 claims description 5
- 206010023497 kuru Diseases 0.000 claims description 4
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 229920001817 Agar Chemical group 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 239000008272 agar Chemical group 0.000 claims description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical group NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 150000001336 alkenes Chemical class 0.000 claims 2
- 125000000129 anionic group Chemical group 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims 2
- 235000012239 silicon dioxide Nutrition 0.000 claims 2
- 239000004408 titanium dioxide Substances 0.000 claims 2
- 241001137251 Corvidae Species 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 239000004576 sand Substances 0.000 claims 1
- 208000008864 scrapie Diseases 0.000 abstract description 3
- 208000024777 Prion disease Diseases 0.000 abstract description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 abstract 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 abstract 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 abstract 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 abstract 1
- 239000012677 causal agent Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 45
- 239000000523 sample Substances 0.000 description 34
- 239000000872 buffer Substances 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 28
- 210000003743 erythrocyte Anatomy 0.000 description 25
- 208000015181 infectious disease Diseases 0.000 description 20
- 239000008280 blood Substances 0.000 description 19
- 238000011049 filling Methods 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 17
- 239000000126 substance Substances 0.000 description 15
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000001471 micro-filtration Methods 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 230000007803 itching Effects 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000028167 Southeast Asian ovalocytosis Diseases 0.000 description 5
- 239000000644 isotonic solution Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- -1 antibodies Proteins 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 102100025818 Major prion protein Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000009434 installation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 125000003700 epoxy group Chemical group 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LTOKKZDSYQQAHL-SECBINFHSA-N trimethoxy-[4-[(2R)-oxiran-2-yl]butyl]silane Chemical compound C([C@@H]1CO1)CCC[Si](OC)(OC)OC LTOKKZDSYQQAHL-SECBINFHSA-N 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- BHMLFPOTZYRDKA-IRXDYDNUSA-N (2s)-2-[(s)-(2-iodophenoxy)-phenylmethyl]morpholine Chemical compound IC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 BHMLFPOTZYRDKA-IRXDYDNUSA-N 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011082 depyrogenation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- CTSNILUMZOPPLK-UHFFFAOYSA-N n,n',n"-trimethylmethanetriamine Chemical group CNC(NC)NC CTSNILUMZOPPLK-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 102000035123 post-translationally modified proteins Human genes 0.000 description 1
- 108091005626 post-translationally modified proteins Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- General Preparation And Processing Of Foods (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/673,147 US5808011A (en) | 1996-07-01 | 1996-07-01 | Method for chromatographic removal of prions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW390887B true TW390887B (en) | 2000-05-21 |
Family
ID=24701495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW086108949A TW390887B (en) | 1996-07-01 | 1997-06-26 | A method for chromatographic removal of prions |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5808011A (enExample) |
| EP (1) | EP0954528B2 (enExample) |
| JP (1) | JP4031833B2 (enExample) |
| CN (2) | CN1743340A (enExample) |
| AT (1) | ATE267212T1 (enExample) |
| AU (1) | AU718557B2 (enExample) |
| BR (1) | BR9710035A (enExample) |
| CA (1) | CA2259632C (enExample) |
| DE (1) | DE69729217T3 (enExample) |
| ES (1) | ES2221957T5 (enExample) |
| TW (1) | TW390887B (enExample) |
| WO (1) | WO1998000441A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040053208A1 (en) * | 1995-08-29 | 2004-03-18 | V. I. TECHNOLOGIES, Inc. | Methods to selectively inactivate parasites in biological compositions |
| US6719988B2 (en) | 1997-02-21 | 2004-04-13 | The Regents Of The University Of California | Antiseptic compositions for inactivating prions |
| US20060008494A1 (en) * | 1997-02-21 | 2006-01-12 | The Regents Of The University Of California | Complete inactivation of infectious proteins |
| US6617119B2 (en) | 1997-02-21 | 2003-09-09 | The Regents Of The University Of California | Assay for specific strains of multiple disease related conformations of a protein |
| US6720355B2 (en) * | 1997-02-21 | 2004-04-13 | The Regents Of The University Of California | Sodium dodecyl sulfate compositions for inactivating prions |
| US6221614B1 (en) | 1997-02-21 | 2001-04-24 | The Regents Of The University Of California | Removal of prions from blood, plasma and other liquids |
| US6620629B1 (en) | 1997-02-21 | 2003-09-16 | The Regents Of The University Of California | Method for detecting prions |
| ATE233275T1 (de) * | 1998-02-11 | 2003-03-15 | Zlb Bioplasma Ag | Verfahren zur entfernung von erregern übertragbarer spongiformer encephalophatien aus proteinlösungen |
| US6139878A (en) * | 1998-04-27 | 2000-10-31 | Aventis Behring, Llc | Method for preparing a diafiltered stabilized blood product |
| US6150172A (en) * | 1999-01-08 | 2000-11-21 | The United States Of America As Represented By The Secretary Of Agriculture | Method and kit for extracting prion protein |
| US6605445B1 (en) * | 1999-02-22 | 2003-08-12 | Bayer Corporation | Rapid method of determining clearance of prion protein |
| US6166187A (en) | 1999-03-05 | 2000-12-26 | The Regents Of The University Of California | Method of concentrating prion proteins in blood samples |
| US6437102B1 (en) * | 1999-11-24 | 2002-08-20 | Bayer Corporation | Method of separating prions from biological materials |
| EP1272509A2 (en) * | 2000-04-05 | 2003-01-08 | V.I. Technologies, Inc. | Prion-binding peptidic ligands and methods of using same |
| US20030050276A1 (en) * | 2001-08-15 | 2003-03-13 | Cunanan Crystal M. | Treatment of tissue, instruments and work surfaces to remove infectious agents |
| EP1345666A1 (en) * | 2000-12-29 | 2003-09-24 | Upfront Chromatography A/S | Extracorporeal capturing of specific bio-macromolecular entities from extracellular body fluids |
| US20020131958A1 (en) * | 2001-01-22 | 2002-09-19 | John Chapman | Method for purifying a biological composition |
| US7577577B2 (en) * | 2001-01-31 | 2009-08-18 | Dell Products L.P. | Pull to customer order demand fulfillment system and method |
| US6518010B2 (en) * | 2001-02-28 | 2003-02-11 | Biopure Corporation | Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier |
| US6613505B2 (en) | 2001-04-12 | 2003-09-02 | Bioresource International, Inc. | Composition and method for destruction of infetious prion proteins |
| US7001715B2 (en) * | 2002-02-28 | 2006-02-21 | Biopure Corporation | Purification of red blood cells by separation and diafiltration |
| AU2003206526A1 (en) * | 2002-02-28 | 2003-09-09 | Zetacon Corporation | Predictive control system and method |
| MXPA04008275A (es) * | 2002-02-28 | 2005-04-25 | Microsens Biophage Ltd | Enlace de formas patologicas de proteinas de prion. |
| GB0214007D0 (en) * | 2002-06-18 | 2002-07-31 | Common Services Agency | Removal of prion infectivity |
| US7863411B2 (en) * | 2002-12-03 | 2011-01-04 | Pathogen Removal and Diagnostics Technologies Inc. | Prion protein ligands and methods of use |
| US7510848B2 (en) * | 2003-04-04 | 2009-03-31 | North Carolina State University | Prion protein binding materials and methods of use |
| WO2004090102A2 (en) | 2003-04-04 | 2004-10-21 | American Red Cross | Prion protein binding materials and methods of use |
| US20050054003A1 (en) * | 2003-09-10 | 2005-03-10 | Stenland Christopher J. | Prion clearance using particulate metal oxides |
| ES2407380T5 (es) | 2004-02-27 | 2017-07-07 | Octapharma Ag | Procedimiento para proporcionar una preparación de anticuerpos purificada, sin riesgo respecto a virus |
| GB0416699D0 (en) * | 2004-07-27 | 2004-09-01 | Prometic Biosciences Ltd | Prion protein ligands and methods of use |
| WO2006108047A2 (en) * | 2005-04-05 | 2006-10-12 | Biopure Corporation | Oxygenated polymerized hemoglobin solutions and their uses for tissue visualization |
| BRPI0611811A2 (pt) * | 2005-06-10 | 2008-12-09 | Prometic Biosciences Ltd | ligantes de ligaÇço À proteÍna |
| US20070128693A1 (en) * | 2005-12-06 | 2007-06-07 | Advantek Serum Laboratories Limited3/F | Method for the inactivation and removal of dengue virus from biological samples |
| RU2410128C2 (ru) * | 2006-07-12 | 2011-01-27 | Асахи Касеи Медикал Ко., Лтд. | Способ удаления патологического прионного белка из продуктов крови |
| KR20090109546A (ko) * | 2006-12-29 | 2009-10-20 | 텍사스 테크 유니버시티 | 생물학적 유체로부터 전염성 해면상 뇌병증 병원체의 직교적 제거 방법 |
| EP2027875A1 (en) * | 2007-08-23 | 2009-02-25 | Octapharma AG | A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC) |
| US10172949B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| KR102170375B1 (ko) | 2009-06-09 | 2020-10-27 | 프로롱 파마슈티컬스, 엘엘씨 | 헤모글로빈 조성물 |
| US10172950B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| CN102675414A (zh) * | 2011-03-08 | 2012-09-19 | 上海天伟生物制药有限公司 | 糖蛋白中去除/灭活朊病毒的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU605901B2 (en) * | 1987-09-11 | 1991-01-24 | Ares Trading S.A. | Purification process |
| JPH0788395B2 (ja) * | 1987-10-23 | 1995-09-27 | シェリング・コーポレーション | タンパク質の精製方法 |
| CA2169191C (en) * | 1993-08-26 | 2008-01-15 | Elizabeth A. Wang | Neural regeneration using human bone morphogenetic proteins |
| DE4429558A1 (de) * | 1994-08-19 | 1996-02-22 | Sanorell Pharma Gmbh & Co | Verfahren zur Herstellung von infektionsfreien pharmazeutischen Präparaten und/oder Nahrungsmitteln aus infektiösem Material |
-
1996
- 1996-07-01 US US08/673,147 patent/US5808011A/en not_active Expired - Lifetime
-
1997
- 1997-06-26 CN CNA2005100039089A patent/CN1743340A/zh active Pending
- 1997-06-26 AT AT97932311T patent/ATE267212T1/de not_active IP Right Cessation
- 1997-06-26 WO PCT/US1997/011149 patent/WO1998000441A1/en not_active Ceased
- 1997-06-26 JP JP50429698A patent/JP4031833B2/ja not_active Expired - Fee Related
- 1997-06-26 BR BR9710035A patent/BR9710035A/pt not_active Application Discontinuation
- 1997-06-26 ES ES97932311T patent/ES2221957T5/es not_active Expired - Lifetime
- 1997-06-26 EP EP97932311A patent/EP0954528B2/en not_active Expired - Lifetime
- 1997-06-26 DE DE69729217T patent/DE69729217T3/de not_active Expired - Lifetime
- 1997-06-26 CA CA002259632A patent/CA2259632C/en not_active Expired - Fee Related
- 1997-06-26 TW TW086108949A patent/TW390887B/zh not_active IP Right Cessation
- 1997-06-26 AU AU35802/97A patent/AU718557B2/en not_active Ceased
- 1997-06-26 CN CNB971953430A patent/CN1283660C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0954528A1 (en) | 1999-11-10 |
| JP4031833B2 (ja) | 2008-01-09 |
| CN1283660C (zh) | 2006-11-08 |
| CA2259632C (en) | 2008-04-08 |
| CN1743340A (zh) | 2006-03-08 |
| AU718557B2 (en) | 2000-04-13 |
| DE69729217T3 (de) | 2012-03-15 |
| HK1019151A1 (en) | 2000-01-14 |
| CN1221425A (zh) | 1999-06-30 |
| WO1998000441A1 (en) | 1998-01-08 |
| EP0954528B2 (en) | 2011-09-07 |
| DE69729217D1 (de) | 2004-06-24 |
| CA2259632A1 (en) | 1998-01-08 |
| BR9710035A (pt) | 1999-08-10 |
| US5808011A (en) | 1998-09-15 |
| ES2221957T3 (es) | 2005-01-16 |
| JP2000513377A (ja) | 2000-10-10 |
| ES2221957T5 (es) | 2012-01-27 |
| ATE267212T1 (de) | 2004-06-15 |
| AU3580297A (en) | 1998-01-21 |
| EP0954528B1 (en) | 2004-05-19 |
| DE69729217T2 (de) | 2005-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW390887B (en) | A method for chromatographic removal of prions | |
| DE69329461T2 (de) | Verfahren zur extraktion und reinigung von hamoglobin | |
| US10562957B2 (en) | Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing the same | |
| JPS58501323A (ja) | 細胞生産抗ウイルス性物質の「ろ」過方法 | |
| WO2006017763A2 (en) | Capture and removal of biomolecules from body fluids using partial molecular imprints | |
| EP3411384B1 (en) | Extraction process from colostrum | |
| JP2008505065A (ja) | ウイルス安全性生物学的流体の調製のための方法 | |
| Foster | The Effect of Downstream Processing Steps on Process Yield and Protein Quality | |
| CA2951735C (en) | Preparation methods for a novel generation of biological safe klh products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents | |
| CN101588822A (zh) | 从生物流体中去除传染性海绵状脑病病原体的正交方法 | |
| KR102024342B1 (ko) | 암 치료용, 접합 치료 백신의 개발용, 및 접종제용으로 사용되는 생물학적으로 안전한 klh 제품의 신규 생성을 위한 제조 방법 | |
| HK1019151B (en) | A method for chromatographic removal of prions | |
| HK1088341A (en) | A method for chromatographic removal of prions | |
| Heldt | Affinity adsorption of viruses using small peptide ligands | |
| US20050224355A1 (en) | Removal of biological contaminants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MM4A | Annulment or lapse of patent due to non-payment of fees |